Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Chemistry ; 26(23): 5157-5161, 2020 Apr 21.
Artigo em Inglês | MEDLINE | ID: mdl-31994220

RESUMO

This work reports that cyclophanes and their [2]catenanes were synthesized by the SN Ar reactions of disubstituted adamantanes bearing halophenol units and 3,6-dichlorotetrazine in moderate yields. In the crystalline state, the cyclophanes had hexagonal structures with a cavity. The [2]catenanes were composed of two macrocycles that were singly interlocked and orthogonally arranged, indicating the construction from eight component molecules through eight C-O bonds in a one-step reaction in up to 33 % yield. The cyclophanes were assembled to afford a supramolecular organic framework in the solid state, which exhibited permanent intrinsic porosity and adsorption of leaf alcohol or aldehyde in a single-crystal to single-crystal fashion. The molecular structures of the liquid guests were determined by single-crystal X-ray analysis. The formation of catenanes and the use of cyclophane-based porous crystals in the crystalline sponge method may be largely ascribed to the solvophobic effects and the van der Waals interactions that originate in the aliphatic and bulky nature of the adamantane units.

2.
Cancer Immunol Immunother ; 63(11): 1189-97, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-25099367

RESUMO

INTRODUCTION: Multiple myeloma (MM) development involves a series of genetic abnormalities and changes in the bone marrow (BM) microenvironment, favoring the growth of the tumor and failure of local immune control. T regulatory (Treg) cells play an important role in dampening anti-tumor immune responses while T-helper-17 (Th17) cells seem to be critical for the eradication of malignant cells. The aim of our study was to characterize the expression of Treg- and Th17-related genes in total myeloma BM samples to assess their role as biomarkers, prognostic factors, and possible therapeutic targets in this incurable disease. METHODS: Expression of markers for Treg (FOXP3, CTLA4) and Th17 cells (RORγt) was determined by quantitative real-time PCR in BM aspirates of 46 MM patients, four patients with monoclonal gammopathy of undetermined significance, five solitary plasmacytomas, and five healthy BM donors. Gene expression was evaluated regarding an influence on the patients' overall survival (OS). RESULTS: FOXP3 and CTLA4 presented a sixfold (p = 0.02) and 30-fold higher expression (p = 0.03), respectively, in MM patients than in controls. RORγt expression was similar in MM patients and controls. Median OS of MM patients was 16.8 (range 4.5-29.1) months, and international staging system was the only independent prognostic factor for patients survival. CONCLUSIONS: Overexpression of FOXP3 and CTLA4 in total BM samples suggests a local accumulation of immunosuppressive Tregs, the MM tumor environment, possibly dampening anti-tumor host immune responses. Therapeutic approaches targeting Treg cells and restoring local anti-tumor immunity may provide new treatment strategies for this incurable malignancy.


Assuntos
Medula Óssea/metabolismo , Antígeno CTLA-4/metabolismo , Fatores de Transcrição Forkhead/metabolismo , Mieloma Múltiplo/metabolismo , Linfócitos T Reguladores/citologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores , Células da Medula Óssea/citologia , Feminino , Regulação Neoplásica da Expressão Gênica , Humanos , Terapia de Imunossupressão , Masculino , Pessoa de Meia-Idade , Gamopatia Monoclonal de Significância Indeterminada/genética , Mieloma Múltiplo/mortalidade , Membro 3 do Grupo F da Subfamília 1 de Receptores Nucleares/metabolismo , Plasmocitoma/genética , Plasmocitoma/metabolismo , Sindecana-1/metabolismo , Células Th17/citologia , Resultado do Tratamento
4.
Cytometry B Clin Cytom ; 86(2): 98-105, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24243815

RESUMO

BACKGROUND: Multiparameter flow cytometry is a useful tool for the diagnostic evaluation of mature B-cell neoplasms (MBN). Recently, it has been shown that CD200 may improve the distinction between chronic lymphocytic leukemia (CLL; CD200+) and mantle cell lymphoma (MCL; CD200-), but the role of CD200 expression in atypical CLL and other MBN remains to be established. METHODS: To address this issue, we investigated the expression of CD200 in 159 consecutive cases of MBN. RESULTS: CD200 was strongly expressed in CLL and was revealed to be an excellent marker to distinguish CLL from MCL, even in cases of atypical CLL. However, lack of CD200 was not an exclusive finding of MCL, being also observed in other MBNs. Furthermore, CD200 was highly expressed in hairy cell leukemia, being useful in the differential diagnosis of lymphomas with villous lymphocytes. Herein, we propose an algorithm to classify CD5+ MBNs based on the expression of CD200, CD11c, heavy chain immunoglobulins, and Matutes score. CONCLUSIONS: These results expand the understanding of the CD200 expression in MBNs, giving further support for the inclusion of this marker in the routine investigation by flow cytometry.


Assuntos
Antígenos CD/análise , Citometria de Fluxo , Leucemia Linfocítica Crônica de Células B/diagnóstico , Adulto , Idoso , Idoso de 80 Anos ou mais , Antígenos CD/imunologia , Diagnóstico Diferencial , Feminino , Humanos , Imunofenotipagem , Leucemia Linfocítica Crônica de Células B/imunologia , Linfoma de Célula do Manto/diagnóstico , Linfoma de Célula do Manto/imunologia , Masculino , Pessoa de Meia-Idade
5.
Artigo em Inglês | MEDLINE | ID: mdl-24039011

RESUMO

Background: Multiparameter flow cytometry is a useful tool for the diagnostic evaluation of mature B-cell neoplasms (MBN). Recently, it has been shown that CD200 may improve the distinction between chronic lymphocytic leukemia (CLL; CD200+) and mantle cell lymphoma (MCL; CD200-), but the role of CD200 expression in atypical CLL and other MBN remains to be established. Methods: To address this issue, we investigated the expression of CD200 in 159 consecutive cases of MBN. Results: CD200 was strongly expressed in CLL and was revealed to be an excellent marker to distinguish CLL from MCL, even in cases of atypical CLL. However, lack of CD200 was not an exclusive finding of MCL, being also observed in other MBNs. Furthermore, CD200 was highly expressed in hairy cell leukemia, being useful in the differential diagnosis of lymphomas with villous lymphocytes. Herein, we propose an algorithm to classify CD5+ MBNs based on the expression of CD200, CD11c, heavy chain immunoglobulins and Matutes score. Conclusions: These results expand the understanding of the CD200 expression in MBNs, giving further support for the inclusion of this marker in the routine investigation by flow cytometry. © 2013 Clinical Cytometry Society.

6.
Biol Pharm Bull ; 25(2): 235-8, 2002 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-11853173

RESUMO

Effect of nonylphenol on aminopyrine N-demethylase activity, a typical drug-metabolizing enzyme activity, by ten kinds of human hepatic cytochrome P450s (CYP) and on progesterone 17alpha-hydroxylase activity by steroidogenic CYP17 was investigated. When determined at 2 mM substrate concentration, nonylphenol (1 mM) most efficiently inhibited aminopyrine N-demethylation by CYP2C9 and CYP2C19, by 61% and 59%, respectively, followed by CYP2D6, CYP1A2, CYP2C18 and CYP2C8 (46-51%), whereas inhibition of the activities by other CYPs was less than 27%. Additionally, nonylphenol competitively inhibited diclofenac 4'-hydroxylation by CYP2C9 and S-mephenytoin 4'-hydroxylation by CYP2C19 with Ki values of 5.3 and 37 microM, respectively. Furthermore, nonylphenol exhibited a competitive inhibition of progesterone 17alpha-hydroxylase activity by CYP17 with Ki value of 62 microM. These results suggest that nonylphenol inhibits human hepatic CYPs, especially CYP2C9 and CYP2C19, and steroidogenic CYP17 activities.


Assuntos
Hidrocarboneto de Aril Hidroxilases , Inibidores das Enzimas do Citocromo P-450 , Fígado/enzimologia , Fenóis/farmacologia , Esteroide 16-alfa-Hidroxilase , Esteroide 17-alfa-Hidroxilase/antagonistas & inibidores , Aminopirina/metabolismo , Aminopirina N-Desmetilase/antagonistas & inibidores , Citocromo P-450 CYP1A2 , Citocromo P-450 CYP2C19 , Citocromo P-450 CYP2C8 , Citocromo P-450 CYP2C9 , Diclofenaco/metabolismo , Relação Dose-Resposta a Droga , Humanos , Oxigenases de Função Mista/antagonistas & inibidores , Esteroide Hidroxilases/antagonistas & inibidores
7.
Rev. bras. hematol. hemoter ; 30(4): 281-286, jul.-ago. 2008. graf, tab
Artigo em Inglês | LILACS | ID: lil-496240

RESUMO

The detection of minimal residual disease (MRD) is an important prognostic factor in childhood acute lymphoblastic leukemia (ALL) providing crucial information on the response to treatment and risk of relapse. However, the high cost of these techniques restricts their use in countries with limited resources. Thus, we prospectively studied the use of flow cytometry (FC) with a simplified 3-color assay and a limited antibody panel to detect MRD in the bone marrow (BM) and peripheral blood (PB) of children with ALL. BM and PB samples from 40 children with ALL were analyzed on days (d) 14 and 28 during induction and in weeks 24-30 of maintenance therapy. Detectable MRD was defined as > 0.01 percent cells expressing the aberrant immunophenotype as characterized at diagnosis among total events in the sample. A total of 87 percent of the patients had an aberrant immunophenotype at diagnosis. On d14, 56 percent of the BM and 43 percent of the PB samples had detectable MRD. On d28, this decreased to 45 percent and 31 percent, respectively. The percentage of cells with the aberrant phenotype was similar in both BM and PB in T-ALL but about 10 times higher in the BM of patients with B-cell-precursor ALL. Moreover, MRD was detected in the BM of patients in complete morphological remission (44 percent on d14 and 39 percent on d28). MRD was not significantly associated to gender, age, initial white blood cell count or cell lineage. This FC assay is feasible, affordable and readily applicable to detect MRD in centers with limited resources.


A detecção de doença residual mínima (DRM) é um importante fator prognóstico na leucemia linfóide aguda (LLA) infantil e fornece informações sobre a resposta ao tratamento e o risco de recaída. Entretanto, os altos custos das técnicas utilizadas limitam seu uso nos países em desenvolvimento. Desta forma, realizamos um estudo prospectivo para avaliar a citometria de fluxo (CF), utilizando três fluorescências e um painel limitado de anticorpos monoclonais, como método de detecção de DRM em medula óssea (MO) e sangue periférico (SP) de crianças com LLA. Amostras de MO e SP de 40 crianças portadoras de LLA foram analisadas nos dias (d)14 e d28 da indução e nas semanas 24-30 da terapia de manutenção. Foram consideradas como DRM+ as amostras que apresentaram > 0,01 por cento das células com o fenótipo aberrante (FA). Oitenta e sete por cento dos pacientes apresentaram FA ao diagnóstico. No d14, 56 por cento das amostras de MO e 43 por cento do SP apresentaram DRM. No d28, foi detectada DRM em 45 por cento e 31 por cento das amostras de MO e SP, respectivamente. A porcentagem de DRM na MO foi similar à do SP nos casos de LLA-T, mas aproximadamente dez vezes maior na LLA de precursor-B. Foi detectada DRM na MO de 44 por cento e 39 por cento dos pacientes que estavam remissão morfológica nos d14 e d28, respectivamente. Não foi demonstrada associação significante entre a presença de DRM e sexo, idade, leucometria inicial e linhagem celular. Esta técnica de detecção de DRM por CF é relativamente barata e pode ser aplicada em centros com recursos limitados.


Assuntos
Humanos , Coleta de Amostras Sanguíneas , Citometria de Fluxo , Neoplasia Residual , Leucemia-Linfoma Linfoblástico de Células Precursoras
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA